 management non-small cell lung cancer Etoposide phase-specific schedule-dependent derivative podophyllotoxin DNA-topoisomerase II Early preclinical work sharp activity mouse leukemias possible synergy cisplatin single agent limited benefit non-small cell lung cancer NSCLC response rates combination cisplatin mainstay chemotherapeutic efforts primary therapy conjunction radiation Response rates advanced disease average patients Stage IIIA IIIB disease recent work issue true synergy etoposide cisplatin NSCLC reassessment relative roles etoposide cisplatin combination unclear several studies Pharmacokinetic data suggest multiple daily fractions etoposide superior prolonged infusions several future trials current major role etoposide cisplatin multimodality therapy combination radiation and/or surgery Several agents etoposide etoposide cisplatin mitomycin vindesine doxorubicin cyclophosphamide ifosfamide carboplatin unclear addition response survival advantage